Emmanuelle Malaurie - Concepedia

Author

Emmanuelle Malaurie

Hôpital Intercommunal de Créteil

Also Known As

E Malaurie, E. Malaurie, Emmanuelle Malaurie

Publications

536

Citations

H-Index

Concepts

All Affiliations

Hôpital Intercommunal de Créteil Institut de Cancérologie de Lorraine Institut de Cancérologie de l'Ouest Institut Gustave Roussy Institut Claudius Regaud

About

Emmanuelle Malaurie is an author at Hôpital Intercommunal de Créteil specializing in medicine, radiation oncology, and oncology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	9	9	256
2	Obstetrics	6	6	115
3	Health Sciences	1	1	42
4	Cell Biology	1	1	16
5	Head And Neck Surgery	1	1	42

Emmanuelle Malaurie

Publications

467

Citations

H-Index

Page 1

	Year	Citations
Expression of the genetic variants of human alpha-1-acid glycoprotein in cancer Jean-Claude Duché, Nicolas Simon, Emmanuelle Malaurie, Clinical Biochemistry Genetic VariantsOncologySomatic VariantOncogenic AgentMedicine	2000	87
Outpatient treatment with subcutaneous interleukin-2 and interferon alfa administration in combination with fluorouracil in patients with metastatic renal cell carcinoma: results of a sequential nonrandomized phase II study. Subcutaneous Administration Propeukin Program Cooperative Group. J.M. Tourani, C. Pfister, J.F. Berdah, Journal of Clinical Oncology	1998	78
Efficacy and Safety of First-line Single-Agent Carboplatin vs Carboplatin Plus Paclitaxel for Vulnerable Older Adult Women With Ovarian Cancer Claire Falandry, Frédérique Rousseau, Marie‐Ange Mouret‐Reynier, JAMA Oncology	2021	78
Randomized clinical trial of post-operative radiotherapy versus concomitant carboplatin and radiotherapy for head and neck cancers with lymph node involvement S. Racadot, Mariette Mercier, Sophie Dussart, Radiotherapy and Oncology Neuro-oncologyRandomized Clinical TrialRadiation TherapyMedicineLymph Node Involvement	2008	42
Neoadjuvant chemotherapy with or without nintedanib for advanced epithelial ovarian cancer: Lessons from the GINECO double-blind randomized phase II CHIVA trial Gwénaël Ferron, Gaëtan De Rauglaudre, Stéphanie Bécourt, Gynecologic Oncology Neoadjuvant ChemotherapyMedicineMetronomic TherapyGynecologyGineco Double-blind	2023	27
Role of lipoproteins in the plasma binding of SDZ PSC 833, a novel multidrug resistance‐reversing cyclosporin Nicolas Simon, Éric Dailly, Olivier Combes, British Journal of Clinical Pharmacology	1998	23
A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer Félix Blanc‐Durand, Elisa Yaniz‐Galende, Alba Llop‐Guevara, Gynecologic Oncology Genome InstabilityGynecologyRecombination DynamicCancer GeneticsRad51 Functional Assay	2023	23
Epirubicin/paclitaxel/carboplatin (TEC) vs paclitaxel/carboplatin (TC) in first-line treatment of ovarian cancer (OC) FIGO stages IIB–IV. An AGO-GINECO Intergroup phase III trial Andreas du Bois, M. Combe, Justine Rochon, Journal of Clinical Oncology Vs Paclitaxel/carboplatinResidual TumorOncologyMedicineChemotherapy	2004	20
Impact of adding nintedanib to neoadjuvant chemotherapy (NACT) for advanced epithelial ovarian cancer (EOC) patients: The CHIVA double-blind randomized phase II GINECO study. Gwénaël Ferron, Gaëtan De Rauglaudre, Annick Chevalier, Journal of Clinical Oncology Surgical OncologyCancer ManagementGynecologyPharmacotherapyArm B	2019	16
Evaluation of a RAD51 functional assay in advanced ovarian cancer, a GINECO/GINEGEPS study. Félix Blanc‐Durand, Elisa Yaniz, Catherine Genestie, Journal of Clinical Oncology Brcam EocGynecologyPathologyCancer BiologyTumor Biology	2021	16

Page 1